- Home
- GAN vs AVTX Comparison
GAN vs AVTX Comparison
Compare GAN & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAN
- AVTX
- Stock Information
- Founded
- GAN 1999
- AVTX 2011
- Country
- GAN United States
- AVTX United States
- Employees
- GAN N/A
- AVTX N/A
- Industry
- GAN Computer Software: Programming Data Processing
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- GAN Technology
- AVTX Health Care
- Exchange
- GAN Nasdaq
- AVTX Nasdaq
- Market Cap
- GAN 81.1M
- AVTX 88.4M
- IPO Year
- GAN 2020
- AVTX 2015
- Fundamental
- Price
- GAN $1.74
- AVTX $4.41
- Analyst Decision
- GAN
- AVTX Strong Buy
- Analyst Count
- GAN 0
- AVTX 7
- Target Price
- GAN N/A
- AVTX $34.33
- AVG Volume (30 Days)
- GAN 169.0K
- AVTX 69.6K
- Earning Date
- GAN 05-08-2025
- AVTX 05-12-2025
- Dividend Yield
- GAN N/A
- AVTX N/A
- EPS Growth
- GAN N/A
- AVTX N/A
- EPS
- GAN N/A
- AVTX N/A
- Revenue
- GAN $134,998,000.00
- AVTX $441,000.00
- Revenue This Year
- GAN $12.60
- AVTX N/A
- Revenue Next Year
- GAN $5.02
- AVTX N/A
- P/E Ratio
- GAN N/A
- AVTX N/A
- Revenue Growth
- GAN 4.31
- AVTX N/A
- 52 Week Low
- GAN $1.17
- AVTX $4.44
- 52 Week High
- GAN $1.90
- AVTX $17.49
- Technical
- Relative Strength Index (RSI)
- GAN 47.45
- AVTX 29.58
- Support Level
- GAN $1.71
- AVTX $4.59
- Resistance Level
- GAN $1.76
- AVTX $5.85
- Average True Range (ATR)
- GAN 0.04
- AVTX 0.85
- MACD
- GAN -0.00
- AVTX -0.21
- Stochastic Oscillator
- GAN 64.29
- AVTX 2.41
About GAN GAN Limited
GAN Ltd provides Software-as-a-Service solutions for online casino gaming and sports betting applications. The company has two operating segments B2B and B2C. The B2B segment develops, markets, and sells instances of GameSTACK, GAN Sports, and iSight Back Office technology that incorporates comprehensive player registration, account funding, and back-office accounting and management tools that enable the casino operators to efficiently, confidently, and effectively extend their presence online in places that have permitted online real money gaming, and The B2C segment, which includes the operations of Coolbet, develops and operates a B2C online sports betting and casino platform that is accessible through its website in markets across Northern Europe, Latin America, and Canada.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).